<DOC>
	<DOCNO>NCT00659217</DOCNO>
	<brief_summary>Mesenchymal Stem Cell ( MSC ) show immunosuppressive repairing property . Manifestations systemic lupus eryhematosus ( SLE ) may patient ameliorate medication suppress immune system . Nevertheless , remain subset SLE patient current strategy insufficient control disease . The investigator infuse expand autologous MSC patient lupus Nephritis . The purpose trial evaluate whether new therapeutical approach result improvement lupus disease .</brief_summary>
	<brief_title>Effect Mesenchymal Stem Cell Transplantation Lupus Nephritis</brief_title>
	<detailed_description>Mesenchymal stem cell ( MSC ) , marrow stromal cell , multipotential cell reside within bone marrow induce differentiate various component marrow microenvironment , bone , adipose stromal tissue proper condition . It report MSCs suppress maturation , activation proliferation T , B , NK DC cell vitro downregulate immune response vivo . MSCs presently cotransplantated hematopoietic stem cell , facilitate engraftment hematopoietic stem cell prevent GVHD . Systemic lupus erythematosus ( SLE ) autoimmune disorder affect many organ system . Autoimmune diseases illness occur body 's tissue attack immune system . Patients lupus produce abnormal antibody blood target tissue within body . Because antibody accompany cell inflammation involve tissue anywhere body , lupus potential affect variety area body . The origin autoantibody production SLE unclear role suggest antigen driven process , spontaneous B-cell hyper-responsiveness , impair immune regulation . The BXSB mouse strain spontaneously develop progressive lethal autoimmune disease , similar human SLE . In previous work find transplantation MSCs could alleviate symptom BXSB mouse . This study evaluate safety effectiveness expand autologous MSC infusion patient primary treatment -refractory SLE . This study last 2 year . Participants assign receive either prednisone ( Group 1 ) MSC infusion alone ( Group 2 ) . Patients undergo MSC infusion start study Day 0 . One year post- infusion , Patients clinically assess evaluate MSC disease response , participant undergo kidney biopsy 12 Months .</detailed_description>
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<criteria>1 . Ages 18 50 year old . 2 . Meet least 4 11 American College Rheumatology ( ACR ) Classification criterion SLE . 3 . Able give inform consent . 4 . For treatment refractory lupus nephritis , participant must fail pulse cyclophosphamide , renal biopsy must obtain document either class III IV glomerulonephritis . 1 . Pregnant woman . 2 . Previous history malignancy 3 . Active infection include hepatitis B , hepatitis C , HIV , TB determine positive skin test clinical presentation , treatment suspect TB . 4 . Evidence cardiovascular disease , exist congestive cardiac failure physical exam and/or acute coronary syndrome past 6 month . 5 . Psychiatric illness mental deficiency make compliance treatment inform consent impossible . 6 . Transaminases great 2 time normal unless due active lupus . 7 . Any illness opinion investigator would jeopardize ability Patient tolerate treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Mesenchymal Stem Cells</keyword>
	<keyword>lupus Nephritis</keyword>
</DOC>